A leader in developing therapeutics using advanced molecular biology-based drug delivery technologies, Nastech Pharmaceuticals Company Inc. announced yesterday that it has entered into a multi-compound, feasibility study agreement with Novo Nordisk A/S with respect to certain Novo Nordisk therapeutic compounds.
Novo Nordisk A/S is a world-leader in therapies for metabolic disease. The specific compounds and indications that these two companies will venture into were not announced. Financial and other terms were not disclosed either.
Source: Nastech News For some more merger news in the pharma industry, head on to a recent post at LegalMandA.
Comment Preview